All Stories

  1. Intensive cholesterol-lowering treatment reduces synovial inflammation during early collagenase-induced osteoarthritis, but not pathology at end-stage disease in female dyslipidemic E3L.CETP mice
  2. Proof-of-concept study for liver-directed miQURE technology in a dyslipidemic mouse model
  3. Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
  4. Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation
  5. IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model
  6. A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo
  7. The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis
  8. Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice
  9. Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers
  10. Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs
  11. Common Variants Associated With OSMR Expression Contribute to Carotid Plaque Vulnerability, but Not to Cardiovascular Disease in Humans
  12. Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?
  13. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men
  14. No effects of PCSK9-inhibitor treatment on spatial learning, locomotor activity, and novel object recognition in mice
  15. Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering
  16. In Vivo Magnetic Resonance Imaging‐Based Detection of Heterogeneous Endothelial Response in Thoracic and Abdominal Aorta to Short‐Term High‐Fat Diet Ascribed to Differences in Perivascular Adipose Tissue in Mice
  17. Effects of Inhibition or Deletion of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) on Intracerebral Hemorrhage Volumes in Mice
  18. Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative
  19. Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice
  20. Triple therapy to treat atherosclerosis
  21. Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans
  22. The Structurally Engineered Fatty Acid Icosabutate Improves Lipid Metabolism And Reduces Severity Of Atherogenesis In Mice
  23. Triple Treatment With Alirocumab And Evinacumab On Top Of Atorvastatin Regresses Lesion Size And Improves Plaque Phenotype In Apoe*3leiden.Cetp Mice
  24. Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
  25. FRI0528 HIGH INTENSIVE THERAPEUTIC LOWERING OF SYSTEMIC CHOLESTEROL DOES NOT AMELIORATE OA DEVELOPMENT IN KNEE JOINTS OF HUMANIZED DYSLIPIDEMIC MICE
  26. Common variants associated with OSMR expression contribute to carotid plaque vulnerability, but not to cardiovascular disease in humans
  27. The APOE∗3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis
  28. Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice
  29. Inflammatory cytokine oncostatin M induces endothelial activation in macro- and microvascular endothelial cells and in APOE*3Leiden.CETP mice
  30. The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
  31. Elafibranor Reverses Nonalcoholic Steatohepatitis and Blocks Progression of Fibrosis in APOE*3.Leiden.CETP Mice
  32. Inflammatory Cytokine Oncostatin M Induces Endothelial Activation in vitro and in APOE*3Leiden.CETP Mice
  33. Results, meta-analysis and a first evaluation of UNOxR, the urinary nitrate-to-nitrite molar ratio, as a measure of nitrite reabsorption in experimental and clinical settings
  34. Variable cartilage degradation in mice with diet-induced metabolic dysfunction: food for thought
  35. Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis
  36. Cardiovascular safety of BCR-ABL1 tyrosine kinase inhibitors: imatinib and ponatinib decrease plasma cholesterol and atherosclerosis in APOE3*Leiden.CETP Mice
  37. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
  38. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
  39. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase
  40. Affitope-based anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) vaccine (AT04A) reduces atherosclerosis in APOE*3Leiden.CETP mice
  41. The APOE*3Leiden.GK +/- mouse as novel translational model for dyslipidemia, type 2 diabetes and macrovascular complications
  42. Comment on “Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice” by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46–54
  43. Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes
  44. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9
  45. Treatment of cardiovascular disease: contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising
  46. No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study
  47. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE
  48. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
  49. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
  50. Alirocumab, monoclonal antibody to PCSK9, dose-dependently decreases atherosclerosis, improves plaque stability and shows additive effects with atorvastatin in apoe*3leiden.cetp mice
  51. APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome
  52. Metformin Lowers Plasma Triglycerides by Promoting VLDL-Triglyceride Clearance by Brown Adipose Tissue in Mice
  53. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice
  54. Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol
  55. Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice
  56. Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis
  57. Osteoarthritis development is induced by increased dietary cholesterol in APOE*3Leiden.CETP mice, a translational model for atherosclerosis, and can be inhibited by atorvastatin
  58. Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion
  59. Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice
  60. P40—Perfluorohexanesulfonate and perfluorooctanesulfonate decrease plasma cholesterol and triglycerides in APOE*3LEIDEN.CETP mice by reducing VLDL production and increasing VLDL and HDL clearance
  61. P52—Distribution of perfluorooctanesulfonate and perfluorooctanoate into human plasma lipoprotein fractions over a wide range of concentrations
  62. Distribution of perfluorooctanesulfonate and perfluorooctanoate into human plasma lipoprotein fractions
  63. PO32 La réduction des VLDL-triglycerides plasmatiques par la metformine est due à une augmentation spécifique de leur clairance par le tissu adipeux brun chez la souris APOE*3-Leiden. CETP
  64. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin
  65. PS16 - 80. VLDL-lowering effects of metformin in APOE*3-Leiden.CETP mice, a transgenic model for human-like lipoprotein metabolism
  66. Perfluoroalkyl Sulfonates Cause Alkyl Chain Length-Dependent Hepatic Steatosis and Hypolipidemia Mainly by Impairing Lipoprotein Production in APOE*3-Leiden CETP Mice
  67. 172 NIACIN, ATORVASTATIN AND FENOFIBRATE DECREASE PLASMA CETP BY REDUCTION OF THE HEPATIC MACROPHAGE CONTENT IN APOE*3-LEIDEN.CETP MICE
  68. 181 ADDITIVE EFFECTS OF NIACIN ON TOP OF SIMVASTATIN TREATMENT IN REDUCING ATHEROSCLEROSIS IN APOE*3LEIDEN.CETP MICE
  69. 244 APOE*3LEIDEN.CETP TRANSGENIC MICE AS MODEL FOR THE METABOLIC SYNDROME
  70. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels
  71. P181 - Effets hypocholestérolémiants de la metformine chez la souris APOE*3-Leiden. CETP, un modèle transgénique au profil lipoprotéique humanisé
  72. P28 RESVERATROL PROTECTS AGAINST ATHEROSCLEROSIS DEVELOPMENT IN APOE*3-LEIDEN.CETP MICE
  73. P70 THE EFFECT OF ALISKIREN ON ATHEROSCLEROSIS DEVELOPMENT IN APOE*3LEIDEN.CETP TRANSGENIC MICE WITH AND WITHOUT TREATMENT WITH ATORVASTATIN
  74. P328 APOE*3LEIDEN.CETP TRANSGENIC MICE AS MODEL FOR THE METABOLIC SYNDROME
  75. Fenofibrate Increases Very Low Density Lipoprotein Triglyceride Production Despite Reducing Plasma Triglyceride Levels in APOE*3-Leiden.CETP Mice
  76. Plasma pre β-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein
  77. CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice
  78. Abstract: P982 PREGNANE X RECEPTOR AGONISM DECREASES PLASMA HDL LEVELS IN APOE*3-LEIDEN.CETP MICE
  79. Abstract: P984 PPAR Δ AGONIST GW501516 STRONGLY PREVENTS DEVELOPMENT OF ATHEROSCLEROSIS IN APOE*3LEIDEN MICE
  80. Abstract: P980 PERFLUOROHEXANESULFONATE AND PERFLUOROOCTANESULFONATE DECREASE PLASMA CHOLESTEROL AND TRIGLYCERIDES IN APOE*3LEIDEN.CETP MICE BY REDUCING VLDL PRODUCTION AND INCREASING VLDL AND HDL CLEARANCE
  81. Abstract: P479 RESVERATROL PROTECTS AGAINST ATHEROSCLEROSIS DEVELOPMENT IN APOE*3-LEIDEN.CETP MICE
  82. Abstract: P482 NOVEL LXR AGONIST AZ876 REDUCES ATHEROSCLEROSIS WITHOUT INCREASING TRIGLYCERIDES IN PLASMA AND LIVER
  83. Abstract: P201 APOE*3LEIDEN.CETP TRANSGENIC MICE AS MODEL FOR THE METABOLIC SYNDROME
  84. Abstract: P202 APOE*3LEIDEN-HCETP MICE AS MODEL TO UNRAVEL MECHANISMS UNDERLYING LIPID METABOLISM DISTURBANCES INDUCED BY HIV1 PROTEASE INHIBITORS
  85. Abstract: 533 BEXAROTENE INDUCES DYSLIPIDEMIA BY INCREASED VLDL PRODUCTION AND CETP-MEDIATED REDUCTION OF HDL
  86. Bexarotene Induces Dyslipidemia by Increased Very Low-Density Lipoprotein Production and Cholesteryl Ester Transfer Protein-Mediated Reduction of High-Density Lipoprotein
  87. The dual PPARα/γ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice
  88. PXR agonism decreases plasma HDL levels in ApoE⁎3-Leiden.CETP mice
  89. Preferential campesterol incorporation into various tissues in apolipoprotein E*3-Leiden mice consuming plant sterols or stanols
  90. Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE*3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban)*
  91. Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice
  92. Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin
  93. DUAL PPAR-ALPHA/GAMMA AGONIST TESAGLITAZAR BLOCKS PROGRESSION OF PRE-EXISTING ATHEROSCLEROSIS IN APOE*3LEIDEN.CETP TRANSGENIC MICE
  94. The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus
  95. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice
  96. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice
  97. The Cholesterol-Raising Factor from Coffee Beans, Cafestol, as an Agonist Ligand for the Farnesoid and Pregnane X Receptors
  98. YI-792 NIACIN DECREASES PLASMA CHOLESTEROL AND TRIGLYCERIDES AND INCREASES HDL IN APOE*3LEIDEN. CETP TRANSGENIC MICE. REDUCED CETP LEVELS AND HEPATIC LIPASE ACTIVITY
  99. PO4-98 PERFLUOROHEXANESULFONATE AND PERFLUOROOCTANESULFONATE DECREASE PLASMA CHOLESTEROL AND TRIGLYCERIDES IN APOE*3LEIDEN TRANSGENIC MICE. INDICATION FOR A PPARα AGONIST MECHANISM
  100. PO10-274 RATIO OF PLASMA OXIDIZED LOW-DENSITY LIPOPROTEIN AND ANNEXIN A5 POSITIVELY RELATES TO SEVERITY OF CARDIOVASCULAR DISEASE
  101. Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
  102. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
  103. Plasma annexin A5 level relates inversely to the severity of coronary stenosis
  104. Cholesterol 7 -Hydroxylase Deficiency in Mice on an APOE*3-Leiden Background Increases Hepatic ABCA1 mRNA Expression and HDL-Cholesterol
  105. Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects
  106. ID: 135 Products of limited elastase/cathepsin G degradation of fibrinogen as new biomarker in cardiovascular disease.
  107. Fenofibrate Reduces Atherogenesis in ApoE*3Leiden Mice: Evidence for Multiple Antiatherogenic Effects Besides Lowering Plasma Cholesterol
  108. Fenofibrate reduces the development of atherosclerosis in ApoE⁎3-Leiden transgenic mice: Evidence for anti-atherogenic effects beyond cholesterol-lowering
  109. CETP expression decreases HDL and severely aggravates atherosclerosis in ApoE*⁎3-Leiden mice
  110. Fish Oil Increases Bile Acid Synthesis in Male Patients with Hypertriglyceridemia
  111. Anti-Atherosclerotic Effect of Amlodipine, Alone and in Combination With Atorvastatin, in APOE*3-Leiden/hCRP Transgenic Mice
  112. Th-W61:2 Leptin deficiency in APOE*3Leiden transgenic mice. A new mouse model with combined insulin resistance and atherosclerosis
  113. Th-P16:263 Torcetrapib inhibits cholesteryl ester transfer protein and increases HDL in CTEP.ApoE*3-Leiden transgenic mice
  114. We-P11:215 The thromboxane receptor antagonist S 18886 (Terutroban) favored atherosclerosis regression in APOE*3 Leiden transgenic mice
  115. Genetic variation in the rate-limiting enzyme in cholesterol catabolism (cholesterol 7α-hydroxylase) influences the progression of atherosclerosis and risk of new clinical events
  116. No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice
  117. Coffee Oil Consumption Increases Plasma Levels of 7α-Hydroxy-4-cholesten-3-one in Humans
  118. W12-P-082 Subjects presenting with clinical suspect symptoms for CAD but having normal angiogram and lipid profile exhibit elevated plasma oxidized LDL
  119. Modification of Low-Density Lipoprotein by Methylglyoxal Alters its Physico-Chemical and Biological Properties
  120. Rosuvastatin Reduces Plasma Lipids by Inhibiting VLDL Production and Enhancing Hepatobiliary Lipid Excretion in ApoE*3-Leiden Mice
  121. Absence of an atheroprotective effect of the garlic powder printanor in APOE*3-Leiden transgenic mice
  122. Effect of Low Dose Atorvastatin Versus Diet-Induced Cholesterol Lowering on Atherosclerotic Lesion Progression and Inflammation in Apolipoprotein E*3-Leiden Transgenic Mice
  123. α-Tocopherol levels in plasma in new-onset, insulin-dependent diabetes mellitus
  124. Serum carotenoids and vitamins in relation to markers of endothelial
  125. CYP7A1 A-278C Polymorphism Affects the Response of Plasma Lipids after Dietary Cholesterol or Cafestol Interventions in Humans
  126. Modulating effect of the A-278C promoter polymorphism in the cholesterol 7alpha-hydroxylase gene on serum lipid levels in normolipidaemic and hypertriglyceridaemic individuals
  127. Evidence for anti-inflammatory activity of statins and PPAR  activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro
  128. Well-Characterized Garlic-Derived Materials Are Not Hypolipidemic in APOE*3-Leiden Transgenic Mice
  129. Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol
  130. W01.43 Evidence for anti-inflammatory activity of statins and fibrates from studies in human C-reactive protein transgenic mice and in cultured human hepatocytes
  131. Cholesterol 7 -Hydroxylase Deficiency in Mice on an APOE*3-Leiden Background Impairs Very-Low-Density Lipoprotein Production
  132. Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterol-Lowering Effect in APOE*3-Leiden Transgenic Mice: Evidence for Antiinflammatory Effects of Rosuvastatin
  133. Soluble intercellular adhesion molecule 1 and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other
  134. Genetic Analysis of Indicators of Cholesterol Synthesis and Absorption: Lathosterol and Phytosterols in Dutch Twins and Their Parents
  135. Genetic Analysis of Indicators of Cholesterol Synthesis and Absorption: Lathosterol and Phytosterols in Dutch Twins and Their Parents
  136. Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus
  137. Differential Effects of Amlodipine and Atorvastatin Treatment and Their Combination on Atherosclerosis in ApoE*3-Leiden Transgenic Mice
  138. Safety of long-term consumption of plant sterol esters-enriched spread
  139. Increased Fecal Bile Acid Excretion in Transgenic Mice With Elevated Expression of Human Phospholipid Transfer Protein
  140. Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects
  141. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus
  142. Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice
  143. 4P-1178 Direct in vivo down-regulation of IL-1-induced C-reactive protein (CRP) expression by statins and fibrates in human CRP transgenic mice
  144. 2P-0562 Rosuvastatin reduces atherosclerosis development beyond and independently of its plasma cholesterol-lowering effect in APOE∗3-Leiden transgenic mice. Evidence for anti-inflammatory effects of rosuvastatin
  145. 2P-0569 The novel bile acid reabsorption inhibitor B1-1 lowers plasma cholesterol levels by reduction of VLDL-cholesterol production in apoE∗3-Leiden mice
  146. 2P-0570 The PPAR-α-agonist fenofibrate reduces development of atherosclerosis beyond and independently of its plasma cholesterol-lowering effect in APOE∗3-Leiden transgenic mice
  147. 3P-0737 Bile acid metabolism in hypertriglyceridemic patients. Effects of body mass index and triglyceride-lowering therapy by bezafibrate and fish-oil
  148. 3P-0740 Low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol
  149. Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice
  150. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation
  151. HOE 402 lowers serum cholesterol levels by reducing VLDL-lipid production, and not by induction of the LDL receptor, and reduces atherosclerosis in wild-type and LDL receptor-deficient mice
  152. Design of a Targeted Peptide Nucleic Acid Prodrug To Inhibit Hepatic Human Microsomal Triglyceride Transfer Protein Expression in Hepatocytes †
  153. Increased lipogenesis and resistance of lipoproteins to oxidative modification in two patients with glycogen storage disease type 1a
  154. Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator-Activated Receptor- -Mediated Downregulation of Cholesterol 7 -Hydroxylase and Sterol 27-Hydroxylase Expression
  155. Raman Spectroscopic Evaluation of the Effects of Diet and Lipid-Lowering Therapy on Atherosclerotic Plaque Development in Mice
  156. Dietary vegetable oil and wood derived plant stanol esters reduce atherosclerotic lesion size and severity in apoE3-Leiden transgenic mice
  157. The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia: The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia
  158. Dietary Plant Stanol Esters Reduce VLDL Cholesterol Secretion and Bile Saturation in Apolipoprotein E*3-Leiden Transgenic Mice
  159. Concurrently increased cholesterol synthesis and decreased cholesterol absorption in hypertriglyceridemia. Effects of bezafibrate therapy
  160. Increased fecal bile acid excretion in transgenic mice overexpressing human plasma phospholipid transfer protein
  161. Association of the A-278C promoter polymorphism in the cholesterol 7alpha-hydroxylase gene with hyperlipidemic disorders
  162. Dose dependent effects of atorvastatin on C-reactive protein in type 2 diabetes mellitus
  163. Quantitative evaluation of the effects of amlodipine and atorvastatin on atherosclerotic plaque formation in mice by raman spectroscopy
  164. Long term dietary vitamin E reduces atherosclerotic lesion size and increases plaque stability in heterozygous LDL-receptor deficient mice
  165. Acyl-CoA:Cholesterol Acyltransferase Inhibitor Avasimibe Reduces Atherosclerosis in Addition to Its Cholesterol-Lowering Effect in ApoE*3-Leiden Mice
  166. Dietary cholesterol does not normalize low plasma cholesterol levels but induces hyperbilirubinemia and hypercholanemia in Mdr2 P-glycoprotein-deficient mice
  167. Normal Oxidative Stress and Enhanced Lipoprotein Resistance to In Vitro Oxidation in Hypertriglyceridemia : Effects of Bezafibrate Therapy
  168. Consumption of black and green tea has no effect on inflammation, haemostasis and endothelial markers in smoking healthy individuals
  169. Consumption of French-press coffee raises cholesteryl ester transfer protein activity levels before LDL cholesterol in normolipidaemic subjects
  170. Accelerated Atherosclerosis by Placement of a Perivascular Cuff and a Cholesterol-Rich Diet in ApoE*3Leiden Transgenic Mice
  171. New HMG-CoA reductase inhibitor ZD4522 lowers plasma lipids and VLDL production in APOE*3Leiden transgenic mice
  172. Effects of amlodipine and atorvastatin on the development of atherosclerosis in ApoE*3-Leiden transgenic mice
  173. Long term vitamin E feeding attenuates aortic atherosclerosis independent of plasma lipid levels in heterozygous LDL-receptor deficient mice
  174. Dietary vegetable-, wood- or vegetable/wood-derived stanol esters reduce atherosclerotic lesion size and severity in APOE*3-Leiden transgenic mice
  175. The effect of apolipoprotein(a)-, apolipoprotein E-, and apolipoprotein A4- polymorphisms on quantitative lipoprotein(a) concentrations
  176. Cafestol Increases Serum Cholesterol Levels in Apolipoprotein E*3-Leiden Transgenic Mice by Suppression of Bile Acid Synthesis
  177. Glycogen storage disease type 1a patients with severe hyperlipidemia are protected from premature onset of atherosclerosis by resistance of lipoproteins to oxidative modification
  178. Fibrates suppress bile acid synthesis via PPAR-mediated down-regulation of cholesterol 7-hydroxylase gene expression
  179. Cafestol, the cholesterol-raising factor in boiled coffee, increases serum cholesterol levels in apolipoprotein E3-Leiden transgenic mice by suppression of bile acid synthesis
  180. Acyl-coenzyme A: Cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7?-hydroxylase in cultured rat hepatocytes andin vivo in the rat
  181. Lipoprotein cholesterol uptake mediates up-regulation of bile-acid synthesis by increasing cholesterol 7α-hydroxylase but not sterol 27-hydroxylase gene expression in cultured rat hepatocytes
  182. Lipoprotein cholesterol uptake mediates up-regulation of bile-acid synthesis by increasing cholesterol 7α-hydroxylase but not sterol 27-hydroxylase gene expression in cultured rat hepatocytes
  183. Inhibition of apolipoprotein(a) synthesis in cynomolgus monkey hepatocytes by retinoids via involvement of the retinoic acid receptor
  184. No short-term effect of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses LP-A-I and LP-A-I:A-II in healthy volunteers
  185. Fibrates suppress bile acid synthesis via PPARα-mediated down-regulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase gene expression
  186. βVLDL and IDL but not HDL increase bile acid synthesis by upregulation of cholesterol 7α-hydroxylase gene expression in cultured rat hepatocytes
  187. The coffee diterpene cafestol decreases bile acid synthesis by down-regulation of cholesterol 7α-hydroxylase in apolipoprotein E3-Leiden mice
  188. Effect of dietary stanolesters on hepatic lipid metabolism in APOE*3-Leiden transgenic mice
  189. REGULATION OF BILE ACID BIOSYNTHESIS
  190. Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes (Short Communication)
  191. Plasma coenzyme Q10concentrations are not decreased in male patients with coronary atherosclerosis
  192. Oxidation of LDL and extent of peripheral atherosclerosis
  193. Relationship between Visceral Fat and PAI-1 in Overweight Men and Women before and after Weight Loss
  194. Effects of fenofibrate on hyperlipidemia and postprandial triglyceride metabolism in human apolipoprotein C1 transgenic mice
  195. Role of the peroxisome proliferator-activated receptor-α in the down regulation of fibrinogen gene expression in rodents
  196. Effect of methylglyoxal on the physico-chemical and biological properties of low-density lipoprotein
  197. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?
  198. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.
  199. Effect of fish-oil-enriched margarine on plasma lipids, low-density-lipoprotein particle composition, size, and susceptibility to oxidation
  200. Working group on epidemiology & prevention of the european society of cardiology
  201. Reduced plasma cholesterol and increased fecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice☆☆☆
  202. No Effect of Consumption of Green and Black Tea on Plasma Lipid and Antioxidant Levels and on LDL Oxidation in Smokers
  203. No Effect of Fibrates on Synthesis of Apolipoprotein(a) in Primary Cultures of Cynomolgus Monkey and Human Hepatocytes: Apolipoprotein A-I Synthesis Increased
  204. LDL Oxidation and Extent of Coronary Atherosclerosis
  205. Cafestol, the Cholesterol-Raising Factor in Boiled Coffee, Suppresses Bile Acid Synthesis by Downregulation of Cholesterol 7α-Hydroxylase and Sterol 27-Hydroxylase in Rat Hepatocytes
  206. Mechanism of the slow induction of apolipoprotein A-I synthesis by retinoids in cynomolgus hepatocytes: involvement of retinoic acid and retinoid X receptors
  207. 4.P.98 Effect of methylglyoxal on the physico-chemical and biological properties of low density lipoprotein
  208. 1.P.349 LDL oxidation and risk of coronary atherosclerosis
  209. 4.P.176 Cafestol, the cholesterol-raising factor in boiled coffee, suppresses bile acid synthesis by down-regulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase in rat hepatocytes
  210. 2.P.139 Effects of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses lpA-I and lpA-I: A-II in healthy volunteers
  211. Lipoprotein oxidation, antioxidants and cardiovascular risk: epidemiologic evidence
  212. Effect of 17 -Estradiol on Plasma Lipids and LDL Oxidation in Postmenopausal Women With Type II Diabetes Mellitus
  213. Seasonal Variation in Low Density Lipoprotein Oxidation and Antioxidant Status
  214. Effects of Gemfibrozil and Ciprofibrate on Plasma Levels of Tissue-type Plasminogen Activator, Plasminogen Activator Inhibitor-1 and Fibrinogen in Hyperlipidaemic Patients
  215. Studies on the Mechanism of Fibrate-Inhibited Expression of Plasminogen Activator Inhibitor-1 in Cultured Hepatocytes From Cynomolgus Monkey
  216. Studies on the Role of PPAR in the Fibrate-modulated Gene Expression of Apolipoprotein A-I, Plasminogen Activator Inhibitor 1, and Fibrinogen in Primary Hepatocyte Cultures from Cynomolgus Monkey
  217. Effects of Fish Oil on Oxidation Resistance of VLDL in Hypertriglyceridemic Patients
  218. Altered lipid metabolism in apolipoprotein E-deficient mice does not affect cholesterol balance across the liver
  219. Altered lipid metabolism in apolipoprotein E-deficient mice does not affect cholesterol balance across the liver
  220. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls
  221. Effects of Simvastatin on Plasma Lipids and Apolipoproteins in Familial Hypercholesterolemic Swine
  222. Enhanced susceptibility of low-density lipoproteins to oxidation in coronary bypass patients with progression of atherosclerosis
  223. Induction of liver sterol 27-hydroxylase by bile acid sequestrants in rat
  224. Decreased plasma lathosterol levels in growth hormone deficient men during treatment with growth hormone
  225. Effects of fish oil on oxidation resistance of very low density lipoprotein in hypertriglyceride
  226. Stimulation of cholesterol 7α-hydroxylase by β-VLDL, but not by LDL, in cultured rat hepatocytes
  227. Supplementation with low doses of vitamin E protects low density lipoprotein from lipid peroxidation in men and women
  228. Structural Aspects of Bile Acids Involved in the Regulation of Cholesterol 7alpha-Hydroxylase and Sterol 27-Hydroxylase
  229. Structural Aspects of Bile Acids Involved in the Regulation of Cholesterol 7alpha-Hydroxylase and Sterol 27-Hydroxylase
  230. Heterogeneous expression of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase genes in the rat liver lobulus.
  231. Supplementation With Low Doses of Vitamin E Protects LDL From Lipid Peroxidation in Men and Women
  232. Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase gene transcription
  233. Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol 27-hydroxylase and sterol 7?-hydroxylase gene transcription*1, *2
  234. Suppression of sterol 27-hydroxylase mRNA and transcriptional activity by bile acids in cultured rat hepatocytes
  235. No effect of β-carotene supplementation on plasma lipoproteins in healthy smokers
  236. Co-translational inhibition of apolipoprotein B-100 synthesis by cyclosporin A in the human hepatoma cell line HepG2
  237. Lack of effect of β-carotene supplementation on plasma lipoproteins in healthy smokers
  238. Enhanced susceptibility of LDL to oxidation in coronary bypass patients
  239. Dietary supplementation with vitamin E to protect LDL from lipid peroxidation
  240. Butyrate stimulates the secretion of apolipoprotein B-100-containing lipoproteins from HepG2 cells by inhibiting the intracellular degradation
  241. Cotranslational inhibition of apoB-100 synthesis by cyclosporin A in the human hepatoma cell line HepG2.
  242. Transcriptional regulation of the gene encoding cholesterol 7α-hydroxylase in the rat
  243. Antioxidants and Coronary Heart Disease
  244. Direct suppression of the synthesis of plasminogen activator inhibitor 1 (PAI-1) by gemfibrozil in primary hepatocyte cultures and hep g2 cells
  245. Effect of fish oil and vitamin E on the cardiovascular risk indicators fibrinogen, C-reactive protein and PAI activity in healthy young volunteers
  246. Retinoids stimulate ApoA-I synthesis by induction of gene transcription in primary hepatocyte cultures from cynomolgus monkey (Macaca fascicularis)
  247. Transcriptional regulation of the gene encoding cholesterol 7α-hydroxylase in the rat
  248. Selective inhibition of mitochondrial 27-hydroxylation of bile acid intermediates and 25-hydroxylation of vitamin D 3 by cyclosporin A
  249. Differential feedback regulation of cholesterol 7 α -hydroxylase mRNA and transcriptional activity by rat bile acids in primary monolayer cultures of rat hepatocytes
  250. Lipoprotein(a): relation to other risk factors and genetic heritability. Results from a Dutch parent-twin study
  251. Butyrate stimulates the secretion of apolipoprotein A-I and apolipoprotein B-100 in Hep G2 cells by different mechanisms
  252. Susceptibility of low-density lipoproteins to oxidation in coronary bypass patients
  253. Supplementation with vitamin E but not beta-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro. Effect of cigarette smoking
  254. Apolipoprotein E polymorphism affects plasma levels of lipoprotein(a)
  255. Butyrate stimulates the secretion of apolipoprotein (apo) A-I and apo B100 by the human hepatoma cell line Hep G2. Induction of apo A-I mRNA with no change of apo B100 mRNA
  256. Heterogeneity of rat liver parenchyma in cholesterol 7α-hydroxylase and bile acid synthesis
  257. Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis
  258. Maintenance of bile acid synthesis and cholesterol 7α-hydroxylase activity in cultured rat hepatocytes
  259. One-step solvolysis of 3-, 7- and 12-sulfated free and conjugated bile acids
  260. Bile acids exert negative feedback control on bile acid synthesis in cultured pig hepatocytes by suppression of cholesterol 7α-hydroxylase activity
  261. Cholesterol 7α-hydroxylase activity and bile acid synthesis in hepatocytes of unwearied and weaned pigs in monolayer culture
  262. Differential effects of endotoxin and fibrinogen degradation products (FDPs) on liver synthesis of fibrinogen and albumin: Evidence for the involvement of a novel monokine in the stimulation of fibrinogen synthesis induced by FDPs
  263. Inhibition and induction of bile acid synthesis by ketoconazole effects on bile formation in the rat
  264. Dexamethasone regulates bile acid synthesis in monolayer cultures of rat hepatocytes by induction of cholesterol 7α-hydroxylase
  265. Comparison of taurocholate accumulation in cultured hepatocytes of pig, rat and man
  266. Regulation of plasminogen activator inhibitor 1 synthesis: Studies on the DNA and cellular level
  267. Plasminogen Activator Inhibitor 1: Biosynthesis and mRNA Level Are Increased by Insulin in Cultured Human Hepatocytes
  268. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo
  269. Feedback inhibition of bile acid synthesis in cultured pig hepatocytes
  270. Hydroxylation, conjugation and sulfation of bile acids in primary monolayer cultures of rat hepatocytes
  271. Bile acid synthesis by human hepatoma cell line Hep-G2 is stimulated by low density lipoprotein
  272. Assay of cholesterol 7α-hydroxylase activity in rat hepatocytes in primary monolayer culture
  273. 321 Secretion of protein-C and plasminogen by human hepatocytes: Influence of hormones
  274. Cellular free cholesterol in Hep G2 cells is only partially available for down-regulation of low-density-lipoprotein receptor activity
  275. Regulation of cholesterol metabolism in the liver in vivo and in vitro
  276. Regulation of low density lipoprotein receptor activity in primary cultures of human hepatocytes by serum lipoproteins
  277. Ketoconazole blocks bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat by inhibiting cholesterol 7 alpha-hydroxylase.
  278. Regulation of squalene synthetase activity in rat liver: Elevation by cholestyramine, but no diurnal variation
  279. Stimulation of the LDL receptor activity in the human hepatoma cell line Hep G2 by high-density serum fractions
  280. Regulation of LDL Receptor Activity in Human Hepatocytes
  281. The influence of glucocorticoid on albumin synthesis and its messenger RNA in rat in vivo and in hepatocyte suspension culture
  282. Fibrinogen Fragments X, Y, D and E Increase Levels of Plasma Fibrinogen and Liver mRNAs Coding for Fibrinogen Polypeptides in Rats
  283. Changes in the sequence content of albumin mRNA and in its translational activity in the rat liver with age
  284. Fine structure of exoerythrocytic forms in cultured primary rat hepatocytes
  285. The influence of glucocorticoid on the fibrinogen messenger RNA content of rat liver in vivo and in hepatocyte suspension culture
  286. Restoration Effects of Glucose Refeeding on Reduced Synthesis of Albumin and Total Protein and on Disaggregated Polyribosomes in Liver of Starved Rats: Evidence of a Post-Transcriptional Control Mechanism
  287. Distribution of mRNAs of fibrinogen polypeptides and albumin in free and membrane-bound polyribosomes and induction of α-fetoprotein mRNA synthesis during liver regeneration after partial hepatectomy
  288. Sequence content of α-fetoprotein, albumin and fibrinogen polypeptide mRNAs in different organs, developing tissues and in liver during carcinogenesis in rats
  289. Acute effects of ethanol intake on albumin and total protein synthesis in free and membrane-bound polyribosomes of rat liver
  290. Direct evidence of transcriptional control of fibrinogen and albumin synthesis in rat liver during the acute phase response
  291. Free cytoplasmic messenger ribonucleoprotein complexes from rabbit reticulocytes
  292. Specific poly-A-binding protein of 76,000 molecular weight in polyribosomes is not present on poly A of free cytoplasmic mRNP